Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSBR-1290 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks |
| Cohort 2 | EXPERIMENTAL | Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks |
| Cohort 3 | EXPERIMENTAL | Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks |
| Cohort 4 | EXPERIMENTAL | HOV participants (Cohort 4) will receive multiple-ascending doses of GSBR-1290 or placebo for a total of 12 weeks |
| Cohort 5 | EXPERIMENTAL | Participants with T2DM(Cohort 5) will be randomized to placebo, low-dose, or high-dose arms. Participants in the low-dose, high-dose or placebo arms will receive multiple-ascending doses for 12 weeks |
| Name | Type | Description |
|---|---|---|
| GSBR-1290 | DRUG | Patients will receive GSBR-1290 or matching Placebo |
| Placebo | DRUG | Patients will receive GSBR-1290 or matching Placebo |
Inclusion Criteria cohorts 1-4: 1. Provided evidence of a signed consent 2. Age ≥ 18 and ≤ 75 years 3. Healthy overweight/obese adult men and women with body mass index ≥ 27 and ≤ 40 kg/m2 4. No nicotine use 5. Have a suitable venous access for blood sampling Inclusion Criteria cohort 5: 1. Men a...
GSBR-1290 is being developed for the treatment of overweight or obesity. It is also being studied in people with type 2 diabetes mellitus. It is an investigational small molecule and has not been approved for any indication.
GSBR-1290 targets the GLP-1 receptor, a G protein-coupled receptor (GPCR). By acting on this receptor, it is designed to mimic the effects of the natural incretin hormone GLP-1, which is involved in appetite regulation and glucose metabolism.
GSBR-1290 is being developed by Structure Therapeutics Inc., which trades on the Nasdaq under the ticker GPCR. The company is responsible for the clinical development of the drug.
GSBR-1290 is in Phase 1 clinical development. It has completed one Phase 1b/2a trial. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
GSBR-1290 has been evaluated in a single clinical trial, NCT05762471, titled "Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus." This completed trial enrolled 142 participants in the United States.